Finland
Mineralys Therapeutics Inc (MLYS) Q2 2024 Earnings Call Transcript Highlights: Significant Progress Amid Rising Expenses
Cash, Cash Equivalents, and Investments: $311.1 million as of June 30, 2024, compared to $239 million as of December 31, 2023.R&D Expenses: $39.3 million for Q